Our Team

We launched Monod Bio in 2022 as a spin-out from the Baker Lab at the University of Washington (UW) Institute for Protein Design (IPD). Since then, we are using AI-powered de novo protein design to create RUO tools and IVDs that are faster, cheaper, and more effective.

Daniel Silva Manzano, PhD

Co-Founder, CEO, Board Member

Daniel Silva Manzano is a serial life sciences entrepreneur. He is a co-founder and VP at Neoleukin Therapeutics and currently a Co-Founder and Board Member of Axxis Bio. Daniel has a PhD from the National University of Mexico, Mexico City and is a former senior postdoctoral fellow in Dr. David Baker’s lab at the UW Institute for Protein Design, where he currently serves as a translational advisor.

Alfredo Quijano Rubio, PhD

Co-Founder, CSO, Board Observer

Alfredo Quijano Rubio is a serial life sciences entrepreneur and co-founder at Neoleukin Therapeutics and Axxis Bio. He has a PhD in Bioengineering in Dr. David Baker’s Lab at the UW Institute for Protein Design and is a recipient of the prestigious “La Caixa” Spanish fellowship program.

Greg Tibitts, CPA, MBA

Fractional CFO

Greg Tibbitts is a Certified Public Accountant with over 30 years of professional experience as a senior financial executive and as a board member of publicly traded and privately held companies, primarily in medical diagnostics and life science. He currently serves as a board member for CoImmune Inc, a biotechnology company and served as a board member for IDMI Pharma, Inc.

David Baker, PhD

Founding Director, IPD, Scientific Advisor

David Baker is the Director of the Institute for Protein Design, recipient of the 2024 Nobel Prize in Chemistry, a Howard Hughes Medical Institute Investigator, and a Henrietta and Aubrey Davis Endowed Professor in Biochemistry. He has a PhD in biochemistry with Randy Schekman at the University of California, Berkeley and did postdoctoral work in biophysics with David Agard at UCSF. David has published over 550 peer-reviewed research papers, been granted over 100 patents, and co-founded 17 companies.

Michael Chansler

Advisor

Mr. Chansler brings expertise in business development, strategic relationships management, investor relations, and commercialization for life sciences research, and in-vitro diagnostics products and drug development companies in the US, Europe, and Asia.

Timothy Still, MBA

Executive Board Member

Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. He is an accomplished executive with a career spanning over 34 years in medical diagnostics, devices, and digital health. Mr. Still has been a CEO and Board member at numerous medical technology companies including Sense Biodetection, Myoscience, MDx Health, Gold Standard Diagnostics, Global Kinetics, Xagenic and Accumetrics.

Dave Johnson

Chair, Board of Directors

Chief Executive Officer and founder of Solve Therapeutics. Prior to founding Solve Therapeutics served as Chief Executive Officer at VelosBio, which Merck acquired in late 2020. Before VelosBio, was Chief Executive Officer at Acerta Pharma. He has raised over $700 million in biopharma capital and delivered transactions valued at over $10 billion.

Karan Takhar

Board Member

Senior Managing Director at Matrix Capital Management and board member at Monod Bio, ElevateBio, Koksa Health, Aura Biosciences, Encoded Therapeutics, and Palleon Pharmaceuticals, and Zentalis Pharmaceuticals.

Melina Cimler, PhD

Board Member

SVP of Regulatory & Quality at Adaptive Biotechnologies and Head of Global Quality and Regulatory at Illumina. Previous leadership positions in quality, regulatory, clinical and government regulatory, clinical and government affairs at Beckman Coulter, Abbott Molecular, Gen-Probe, and C.R. Bard. Board of Directors of Monod Bio, Nanostics, and as a member of the Scientific Advisory Board of GRAIL.